NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment - Scoping

Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity (ID6441)

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following potential equality issues were identified:

- Availability of cardiovascular preventative therapies and variable access to specialist weight management services
- Elevated cardiovascular risk in people of South Asian or sub-Saharan African family background
- Socioeconomic status influences the incidence and impact of obesity, compounded by the understanding that people living in England's most deprived areas are almost four times more likely to die prematurely from cardiovascular disease than those in the least deprived
- Compared with the general population, people with severe mental illness are more likely to develop and die from preventable conditions such as cardiovascular disease
- 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE considers technologies within their marketing authorisation for the whole population. Stakeholders will have an opportunity to submit

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity

Issue date: June 2025 1 of 2

evidence on health inequalities. As part of the technology appraisal, the committee will consider the impact of recommendations on people with protected characteristics in conjunction with the principles that guide the development of NICE guidance and standards including the aim to reduce heath inequalities, with the following caveats:

- The committee must follow the processes and methods set out in the NICE health technology evaluation manual and are unable to divert from these methods and processes for individual evaluations or they will risk introducing further inequalities.
- In accordance with NICE's <u>social value judgement</u> principles, no priority is given based on individuals' income, social class, position in life or social roles in guidance developed for the NHS.

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The scope highlights that people from specific family and socioeconomic backgrounds are at an increased risk of CVD.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): ...Janet Robertson......

Date: 09 June 2025